<SEC-DOCUMENT>0001129928-12-000056.txt : 20120912
<SEC-HEADER>0001129928-12-000056.hdr.sgml : 20120912
<ACCEPTANCE-DATETIME>20120912113301
ACCESSION NUMBER:		0001129928-12-000056
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120912
FILED AS OF DATE:		20120912
DATE AS OF CHANGE:		20120912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		121087125

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6K FORM
<TEXT>
<html>
<head>
    <title>form6-k.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Washington, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">Form 6-K</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Report of Foreign Private Issuer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of the Securities Exchange Act of 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the month of&#160;September 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Commission File Number 000-31062</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Translation of registrant&#8217;s name into English)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington Crescent NW</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calgary, Alberta, Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">__________________________________</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;(Address of principal executive offices)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Yes&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">No&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXHIBIT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NUMBER</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="7%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">99.1</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">News Release Dated&#160;&#160;September 12, 2012: Oncolytics Biotech Inc. Provides Update on Phase III Study of REOLYSIN&#174; in Head and Neck Cancers</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="4" valign="top" width="39%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="38%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date:&#160;&#160;September 12, 2012</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="36%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/s/&#160;&#160;Doug Ball</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Doug Ball</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>ex99.htm
<DESCRIPTION>RELEASE
<TEXT>
<html>
<head>
    <title>ex99.htm</title>
    <!--Licensed to: Oncolytics Biotech Inc-->
    <!--Document Created using EDGARizer 2020 5.4.3.1-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right"><br>
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><img src="ex990.jpg" alt=""></font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">210, 1167 Kensington Cr. N.W.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Calgary, Alberta</font></div>

<div style="TEXT-ALIGN: right; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Canada T2N 1X7</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR IMMEDIATE RELEASE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Oncolytics Biotech Inc. Provides Update on Phase III Study of REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174; </font>in Head and Neck Cancers</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, September 12, 2012 ---</font> Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221; or the "Company") (TSX:ONC, NASDAQ:ONCY) today provided an update on its Phase III trial of REOLYSIN in combination with carboplatin and paclitaxel for the treatment of head and neck cancers (REO 018).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has conducted an internal analysis of the blinded combined clinical data for all 80 patients enrolled in the first stage of the study. The study remains blinded at this time. At the time of the analysis, 23 patients of the 80 had not yet progressed but were included for the purposes of analysis. The median evolving progression free survival (PFS) of the 80 patients, which comprises the combined control and test groups, was greater than expected, as was the best response rate. On further examination, it was observed that patients for whom only metastatic disease was being measured by clinicians, were responding differently to treatment than patients who had local regional head and neck disease. Patients in whom only metastatic disease was measured had a median evolving PFS of 120 days, which was statistically significantly greater than those patients with a noted local regional head and neck tumor. There was a statistically significant difference in PFS between these two groups (n=80, p=0.008, hazard ratio=0.536). Oncolytics therefore believes that, based on differential PFS, it has identified two distinct patient groups are being enrolled in this clinical study, patients with local recurrent disease, with or without metastases, and those with distal metastases. Each of these two groups contains patients from both the control and test arms of the study. Oncolytics believes that these two groups of patients must therefore be considered to be different for the purpose of both analysis and investigation.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has consulted with its principal investigators and the independent statistician for the study, and, on September 10, 2012, met with the U.S. Food and Drug Administration in Washington, D.C. Based on these discussions, the Company plans to expand enrollment in the first stage of the study to include 160 patients, all of whom have now been enrolled. Oncolytics intends to introduce an additional segregation to differentiate between patients with local recurrent disease, with or without metastases, and patients with distal metastases. Based on the analysis of the 160 patients, Oncolytics expects to generate randomized data from two discrete patient populations.&#160;&#160;The Company believes this will provide a sufficient number of patients to conduct a meaningful analysis of the two identified patient groups, as well as increased powering for the overall analysis. Oncolytics intends to treat this expanded first stage of the REO 018 clinical trial as a separate supportive study to a planned registration study that will be similar to, and take the place of, the original second stage of the REO 018 clinical trial. Enrollment in the first stage of the study is complete and no additional patients will be enrolled pending approval of a planned registration study. The Company intends to submit protocol amendments to regulators in the immediate near term to reflect these changes. It will require additional time to follow the expanded group of patients and allow the evolving PFS data to mature.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;Segregating and separately evaluating the two identified patient groups means we will be able to obtain our first randomized data in these two patient populations, including one with only metastatic disease,&#8221; said Dr. Brad Thompson, President and CEO of Oncolytics. &#8220;All six of our randomized Phase II studies are examining indications with significant metastatic disease involvement. Patients with metastatic disease represent a large potential market.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Conference Call Details</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr. Brad Thompson, President and CEO of Oncolytics, will host a conference call and webcast on Wednesday, September 12<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>, 2012 at 6:00 a.m. MT (8:00 a.m. ET) to discuss in more depth the Company's Phase III study in head and neck cancers. To access the conference call by telephone, dial 1-647-427-7450 or 1-888-231-8191. A live audio webcast will also be available at the following link: <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.newswire.ca/en/webcast/detail/1034181/1121577</font> or through the Company's website at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com/presentations</font>. Please connect at least 10 minutes prior to the webcast to ensure adequate time for any software download that may be needed. A replay of the webcast will be available at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font> and will also be available by telephone through September 19<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>, 2012. To access the telephone replay, dial 1-416-849-0833 or 1-855-859-2056 and enter reservation number 30393545 followed by the number sign.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>The Company also intends to post the prepared remarks from the call to its corporate website following the call.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Oncolytics Biotech Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font>, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">This press release contains forward-looking statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking information within the meaning of Canadian securities laws. Statements, other than statements of historical facts, included in this press release that address activities, events or developments that Oncolytics expects or anticipates will or may occur in the future, including such things as,&#160;&#160;intended introduction of additional segregation to differentiate between patient groups, enrollment of 160 patients providing sufficient numbers to conduct meaningful analysis of two identified patient groups and increasing power of overall analysis, treatment of expanded first stage of REO 18 clinical trial as separate support to a planned registration study to take the place of original second stage REO 18 clinical trial, anticipated timing for submission of protocol amendments to regulators, the Company's expectations related to the Phase III head and neck cancers trial of REOLYSIN in combination with carboplatin and paclitaxel, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="FONT-STYLE: italic; DISPLAY: inline">and other such matters are forward-looking statements and forward-looking information and involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements and forward-looking information. Such risks and uncertainties include, among others, risks related to the statistical sufficiency of patient enrollment numbers in separate patient groups, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statement and forward-looking information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update these forward-looking statements and forward-looking information, except as required by applicable laws.</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: #ffffff 0.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Equicom Group</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nick Hurst</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW, 10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Floor</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Calgary, Alberta&#160;&#160;T2P 3C4</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel: 403.218.2835</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax: 403.218.2830</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>
</td>
<td align="left" valign="top" width="32%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: #ffffff 0.5pt solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">DGI, LLC</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tom Caden</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20th Floor, 1251 Avenue of the Americas</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">New York, NY&#160;&#160;10020</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Tel:&#160;&#160;212.825.3210</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fax:&#160;&#160;212.825.3229</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">tcaden@dgicomm.com</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">-30-</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex990.jpg
<TEXT>
begin 644 ex990.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`'`!
MX`,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[^****`"BBB@`HK@_B-\2O`_PF\*:EXX^(_BC0/!OA+1K=[G5-
M?\2:K9:/IMHB@;4:YOI8HWGG8B&UMHC)<W5R\5O!%)+*HK\"/VF/^#@'X7^%
MKF_\-_LS_#F]^)NH6WF0)X\\<37?A;P2TQ;8MSI>@11_\)3XCLLA<"\D\)//
MO62TDF159_`S;B;)\CI^TS/&4J#E'GA14N?$3CIJJ6CTOKKU1K2HU*TN6G%R
M[OHO^'/Z,Z*_A\U/_@IU_P`%2?VE=5NM.^&FO>,8DG=E_P"$7_9_^%RS/:^8
M05CBU.PT?Q'XNBB`:)5DGUY[C<"ID=Y,4]/`'_!;K7E&I+<?MYP"<!PC^/\`
MXE^'S@]/^)=-XCTPPX]/LD3?WE&5KY+_`(B5AZUI8#(,\QM+K5CAN2#O:W*U
MSWNKWVL[+4Z/J4OM5J4>WO7[?Y_\,?W`45_#A=?$#_@M)\"5;5M:U#]L_3K&
MS4R3ZCXLT?QE\0=!AC7.Y[NX\2:?XITEX@L99_M$V=I+.NV+(]P^#'_!>W]J
M7P)>VNE_''P3X+^,&CVS^5J$Z:?_`,*[\;J=Z1SD7FE03^&I##MD(M9?"D4\
MKJT,EVB,TR50\3<J]JJ699=FN4M_%4Q>&?LH;;M?O9;K^'2J6^URW5W]0J25
MZ<Z4[;^]:U[>OG]Q_8_17YQ_LG?\%1?V6?VN9+/P_P"$/$L_@KXE7$8W?#'Q
M\+31?$5W.L9:=/#MV+B71O%4:E)&5-%OIM2CME%Q?Z98+N1?T<K[W`YC@LSP
M\,5@,32Q6'FKQJTI<T7W[-6\TCCG"5.3A.+C);KM\]F%%%%=I(4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5\
M1?MM?MR_"?\`8E^&H\9>/9/[8\5:U'=VWP^^'6F7<,>N^,]7MT3>J,Z2#3-!
MTYIH)]:UZXBDMK*(I;P17NK7.GZ9>>W_`+1'Q[\$?LT?"+QG\9OB'<F#POX-
MTB>_EAADC&H:OJCM';:+X=TF*0A)]5U_4Y[;3;%7=(DFG$UP\5K'--'_`!4>
M#_#/[0G_``5X_;(O[[5M0N;&&_G74/$6LE+F\\,_!WX66=]LLM(TN!F0-<1Q
M2_V=I%CNAN/$GB&XNM:U1T,VMZC%\+Q?Q17RI87+,IH_6\\S.7LL)0C[WL4^
M6U>M&VEN;W(-QYK-\RL=>%H1K2G.J[4:4>>>F_97NK;=+^A-K7B#]N'_`(*]
M_'$V%A!>ZWI^G7?VBUT&SN+G1?@W\'M"N9I8([O4;ES-:P7/D-(CZC<KJ7BS
MQ%)%/!8I=8BL(?Z!?V3?^"(7[,WP4L=+U_XTP_\`"_\`XBPK%/<IX@@DM/AO
MI=Z-C21:7X.1E&N11,K1-<^+9=2AOAMO!HVG2L(X_P!.OV</V;?A3^RO\,-'
M^%/PBT"#1M`TV.*6^O6BC?6_$VM&-$OO$7B3441)-3U?4&16DE=4AM85BL-/
M@M=.MK2SM_H"N3(.`L)AI/,L_?\`;&>5Y>UKU<4_;4*$I:NG"C-RI5&M$YU(
M.W*N6,=;U5QTY)TZ'+2HKX7!6<M%>]GY=]VSG?#'A/PWX,TF#0?"F@:)X:T2
MU41VFD>'])L=&TRTC50JQV]CIT%M:Q(J@`*D2XQR3GCHJ**_0J<(TX*$(QA%
M;1A%1BO1+8X@KY2^/'[$W[,?[2VG7-G\8?A#X2\1W\Z2+%XIMM-CT/QG8.X.
M);'Q;HCV.OHT;GS%@FOKBRD8*MU:W$.Z)OJVBL,5@\/C:;I8FC2K4G\4*M*G
M5B]NE2,K;=+?@K5&4H_"VO3R/X\OVV/^")/Q4^!"7_Q3_9;UC7_BMX'TB5M5
MN?";JL7Q8\(QVDANTO\`2FT@6L/C"WL#"D_GZ1!8>)(-D9AT2_6U:\7U7_@F
MQ_P65UWPOJFB?`;]L37)]5\/SSV^@^$_C-K#.-:\,W23_9;?2/B4\B^=JFDO
M))]EC\62J-3T62-3XA-W8?:]6TO^KBOYR/\`@KI_P2QTGQUH7B/]J+]G?P]'
M9?$?2;>^U_XJ>`M%LV6#X@Z9;1-/J/BW0;"#Y(O&FG+F\U:QMX2OBRR6\NHX
M)?$PQK?YEF_"V+X9KRX@X2E44:>N.R5WGAL3A]/:.%*ZNXJ]TE=7W9Z%'$QQ
M"6'Q7O7^"JG:<-5?ET:5_=_\!1_178WUOJ-M#=VDL-Q:W$,5Q;7-O*L]O<6\
MZ[X)X)T_=S0S1%)8I8V>.2-T>-V1E8W*_F'_`."(_P#P4,OK^:Q_8T^,&L2W
MMW':RR?`OQ'JMXSSO::=;2W%]\,[R\G+R3-9V<$NH>#FF=F2QMK_`,/QR+#:
M:!95_3Q7W?#V?83B'+J6883W8O\`=UJ3=YT,3'^)1EHK\K:M*RYNVAQ5J4J-
M24)=-8O^:#^&7E?M=V[L****]PR"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHJAJ6HVVE6=SJ%[+'!9V=K=7EU/(Q5(;>T
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MR\OR5I:.][[*VI1117ZL>>%%%%`!1110`4UE#@JP!!!!#`$$'J"#U!XR.^*=
M10!_$;_P58_9CU3]B;]KS0/BY\)/M/ACPC\1=6'Q2^'E_I,0LK?PC\0]`U:V
MU/Q+H6G+#^[MXM,U?^S_`!%I=JFRT@TS6ETB"$VNFSQ)_6G^R#\?]*_:@_9X
M^%WQOTM8()?&7AFTFU_3K=V,>D>+M,>;1_%VD*KDRI%I_B/3]3@LWE(>YL!:
M7@'EW$;/\5_\%K?@G:_%K]ASQIXBBLTG\0_!;6-'^)NB2B,-,ME9W`T#Q9"9
M0AD6U/A77-4U*:-'C5KK2;"5B3`A7XK_`.#>/XOS:G\-/CQ\$;^Y:0>"_%7A
MOX@^'XI9,F.Q\;:;=Z+KEM!GY8[>RO\`PCIUXZAMAGUV24?/)*J_DV5P7#?'
MF+RF"]GEG$%#ZYAZ$=(1Q,;U$H+_`*^4JU)[72C*UM#NJKZQ@XU9_P`6C:DI
M[NRC%7L]F[KKHE]W](]%%<IXL\:>$?!%G;ZCXR\2^'/"VG7$YM8-0\3:YIN@
MV4MV4,D=I%<ZG<VT,MS*B2.D$;M(R12.!M0FOU:I4A2@ZE1\D(VYF]E?3R1P
MG5T5QGA3XA^!O'0O?^$,\9>$O%9TXPB_'AKQ'I&O?8C<"4PB\_LJ[N1:F98I
M&A$Q0RJCLHPIKLZ5*K"M'GISA4@WI*$N9>=[;/\`2P:K=!FBN/\`%_CKP7X&
M@LKKQIXJ\,>%+6_EE@LKKQ/KVEZ!;W4\*++)!:S:I=6L=Q.L693#$S.(T9V"
MH"PT_#OB70?%FF0ZUX:UG2/$&C7/F?9=6T/4K/5],N?*FEMYA;W]A-/:3&&>
M&2&412OY<L;QOAU901JPE)P4E[2*3E"ZO&_]?U<#=HHHS6@!17*>+/&O@[P1
M8_VGXR\3^'/"^G#/^F^)-<TW0[3MD"XU.YMH2?;?GCZUXA_PV/\`LH?;!8_\
M-(_`S[5NV"'_`(6MX*\SS/\`GF%_M?[^??'O7'6Q^#H3<*N)H4IK>-6M3I/I
MMSR3E:^MEIUW0^6;VBW\GW7Z7_JY]-45R'A/QSX-\;V;:AX,\4^&O%%B-N;O
MP[KNF:Y;<C/,^F7-S$N-R]9.I(('&>OKHI585H\]*<*D'\,H2YD_N\_P$%%&
M:Y#Q=X\\%^`[)=1\:>*_#/A6P8X%[XEU[3-"M>HSBXU.XMXB<9(`;)QCU(*E
M6G1@YU)*$8[MNR5PU>B5V=?17S&G[97[)KW"VJ?M)?`PW#';Y?\`PM7P4&\S
MC"+_`,3?EO7ICCFO</"?CCP?XYL3J?@[Q/X<\4:=QB^\.:WIFMVASG@W&F7-
MS"#[%^]<U',,'B)J%'$X>K-[1I5Z=5_/V<I6\K[ZVV'RR7Q1:^3[+]3K**3(
M]12UVB"BN(\3_$CP!X(FM;?QGXV\'^$)KZ.2:PA\3^)M$T"6]A@=4GEM(]6O
M;1[F.%W1)GA5UB9U5RI9<]'HVLZ;K^G6FL:-J%AJVDZA`EUI^IZ7>V^H6%];
M2Y,=Q:WEI)+;7$+@?++!+)&QR`?ER<H5H3DX*<'4@ESPC)2<;[7`U****U`*
M*\BU;X]_!7P_JE_HGB'XM?#+0-9TR?[-J&D:SX]\+:9JEC<;%D,%[87VJ6]U
M:S>7)')Y4T2-L=&P58$^G:=J5GJMG;ZA87-K>6-W!#=6EY9W$=U:75M<1K-!
M<6US$3%/;S1/'+#-$S1RQNCHS!JQI8BC6<HTZL)RA;FC&2<HW7VENNOW`7Z*
M*X_Q9\0/!'@6.RE\9^+_``MX3BU%YH["7Q/XATK0(KQ[=4>9+635+JV6X:*.
M17D6$R.BLK%=IR*JU848.I4DH0CO)Z)?,#L,T5ROA+QGX2\;V,^I^#?$GAWQ
M3IL%Q]DFU#PUK6G:[917:HLKVDMUIMQ<0Q74<4L4CV[N)4CFC<C:ZDY?B3XH
M?#KP9=0V'C'QWX+\)7MS;B[M+/Q+XJT+0KJZM/-D@-S;V^JWUK+/;^=%)$9X
ME9/,5T)#*:AXFDHJHZD(T7_R\E)15]+6W7X]@.^HKR#_`(:!^!?_`$6;X4>O
M_)1O!_;_`+C%'_#0/P+_`.BS?"C_`,.-X/\`_EQ6/]HX+_H*H?\`@Q?/[M?Z
MV=GV?W'K]%>0?\-`_`O_`*+-\*/_``XO@_\`^7%>IV%];:E;0WMG-!=6ES##
M<6MU:S)<6US;W$2S07%O/'^[F@FB=)(I8RT<B,&1F4@UM1Q-#$<WL:M.KRVY
MN27-:^U[;7L[>@6:W37R+E%8GB'Q'H?A/2;S7O$NL:5H&B:=%YVH:QK>HVFD
MZ781&2.%9;S4+Z6"TM8FFFCB$D\T:&22.,$NZ@X?@[XD_#_X@KJ#>!O'/A#Q
MFNE&V74SX5\2Z+XA_LYKQ9FM5OO['O;P6AN5@G-L)BAG6&5H]P1L7*K3C4A2
M<X*I-2<8.24Y*-KN,=Y)7U[70M=[:';T449K0`HK"\0>)O#_`(5L)-4\2:WH
M^@:;"K-+J&MZI9:38Q;<$^;=W\\%O&`,DEY```22*\#G_;&_90M;IK.X_:/^
M!\-PK!&C;XJ>"P\<O4I(#JXV$9&,%L\],<\M?&87#.*KXBA2<KV56M3I-\MK
MV4Y)NUU>VW4:C-_#%M=;)OJNWS^=CZ9HKA?!OQ,^'GQ!A:X\#^./!_BZ%%1W
MD\+^)=&U]$612REVTJ\NE3*C=ACG;S7=5I1KTZ\.>E.%2#VG3FIP?>S7;L%F
MMTU\@HHS7@GC7]IS]GCX:7DFG>/_`(W?"KP=?Q!O-L-?\?>&-+OXB@#,KV-U
MJ45XK@$[4:`,PP<<\1B<71PL5.M4ITXO[56K3I16V[J2CWZ)^=KH2N]E?TU/
M>Z*^5=+_`&X_V/M:N$M=+_::^!UW.[;%C7XE>$XV+DA0H\[58]S,Q``7/N1Q
MGZ)\.>+/#/BZQ34_"_B'0_$>G2*KI?:#J^GZQ9LK`D%;K3KBX@8'!(*R$$4J
M&-PF);5#$X>LXVNJ5>E5:YKVNH2;5[.U][.WE4H3C\46K]T=#111742%?-W[
M7>M77AS]E/\`:6\163^7>:#^S]\9-9MG5BKK<:;\.?$5Y$R,I5E/FPI\RG<I
M(8<CGZ1KYT_:ST&Z\4?LM_M(>%[%&EO/$?P$^,&@VD2)NDDN=6^'GB&PMT1>
MK,9;A`J#EV*@#G(X<R]H\#BE2O[7ZKB>3??V%3_@6\S2E_%I?]?8?=?7]#^8
M7_@WG\/VE]^U%\8?$$J@W>A_`VYL+-C@M$-=\<>$FN)$R#A]NDI'O&"%D9>0
MY4_V"U_'C_P;U^)K33?VJ/BSX;F=5N/$/P-O[VR!*CS9?#_C;P@TL"$XS(8-
M4DF"C_EG;RL<*A(_L.KXGPO=-\*4/9_]!>-YO7ZQ.WS_`$L=.8?[S+?:._:W
MW][A1117Z(<04444`%%%%`!1110!X!^U%X;M_%_[-WQ]\+W4?G0>(/@M\4]'
MDC">8^+_`,$ZS;*\2'(,\<DB/`0"RRJA3#8=?Y8_^#?+7)K3]K3XH^'MV;77
MO@'K5W+%N8!KC1/'O@(VLNT<,T*:E=!2>@E8#&\U_4I^U=XFMO!O[,7[0OBJ
M[E6*'P_\%/BGJA+/L,LMMX'UM[>WC;*@2W-P(H(?F!,\D0'.`?Y<?^#?#0)K
MS]JSXL>)MC?9?#_P'U.PDE$88+=Z_P"._`[6D1;&4:6+1[UAAAE(9"0=G'Y9
MQ-;_`%XX'5+^*JN)=77_`)<M5?9?BJMK?+9G?A?]SQ?^"/Y(_L5K^>[_`(.(
M/^3:O@A_V7$_^H%XJK^A&OY[O^#B#_DVKX'_`/9<3_Z@?BJOH>/G;A7-_P#L
M&7E_S$4/Z[]M3#"?[S0_Z^1_,_GY^`OB7]IC]BNP^$W[9_PP>5?`GC?5/$?A
M:ZE47EQX7UR3PWJMU:Z[\/?'UFBHL#:E86L6LZ/<-(K*'-WI%W'JFCW@M?[5
M/V+_`-M'X5?MK?"NW^(7P\NDT_6M/6VLO'?@.^NHI/$/@GQ!)$S26-]&JQFZ
MTVX\N2;1M;AA2UU6U5F5+>\@O;&T_,C_`((]?"?X??M"_P#!-'Q/\)/BGH%K
MXH\%ZU\5_B+H^IZ=<@I*ADM/"^I6>H6-TI\[3M5TR\GCOM+U"S\FYL+V"WNX
M'$J;C^0WQO\`@7^TY_P1V_:2T;XJ_"W5M2UCX9:KJ-Q:^$O&-Q;32^'?&7AV
M=Y+F_P#AG\3["U>*"+5XK:',BKY`O'M8?$_AF:SU2S>WT?\`/\CJYGP?EV59
MO2]KC>'<SPN&Q&98=7G5P.)J4XPG7I)I_%RWDMI\JBY1Y/>[JRABIU(3Y88J
MG/D3E)*\(VM'SY=4^UT_(_2W_@XPMW;X7_LS781=D/C[QW`\N1N1KCPWHLD:
M@<$J_P!D9G5>IC4$\U]Q_P#!$W/_``[L^#WMXE^*Z_E\4/%G^-?D7_P56_:Q
M^&W[;?[$'[._QE^'LIL]1T'XRS>'O'W@VYN4GU?P/XHU;P!K.H'2M255B-S8
M7C:)<3:!KBPQVVK6,;2)%;WL&H:=8?KG_P`$3?\`E'9\'^G_`",WQ8Z?]E0\
M6?IZ5[.38JAC/$;'XK#U(UL/B,@H8BC5@VXRI5/J/++RV:L[6MKT1E5A*&"4
M9*THUW%KTB_\S]9*_G?_`."K'_!6;Q)\!/$FH?LX_LZ2V-M\4+&S3_A8?Q"N
M(8M4C\#G5+-+NST#PU9S!K.Y\4_8Y;:]U#4]0M[JPT5+JWM8+:ZU4W*Z;_1!
M7^?1^VCHVK^`?^"@_P`=?^%FVUS-'!^T9KWBK4H[N*25M3\(:[XP?Q9HUW#$
MZCSK#4_"&JV;VL$7[DV\BVL>U00OJ^)&<X_*<HPT,!5>%>8XOZG7QD5[^'HN
MG*<G2E_R[JSY>6,U\-GHS+!4XU*LE-7C&#FX_P`UNGYG[<?LP?\`!'CQ-^T1
MHFD?'+]O[XN?%+Q;XO\`%EG::_:?#Y/$ET^H:;INJ1B]M;?Q7XCUG^TKVVOG
MCD#7?A[08=.BTC*6;:@US#+#!^@US_P1;_X)Z7&E_P!F+\'-5MWV;1JD'Q$^
M((U3(^Z_GR>()(&8>CVS(>Z8XK]/_#^N:1XCT;3->T&_L]3T/6=.L=5T;4["
M>.XL=0TO4+>.YL+VSGC)BEM;F"1)K>2-BLD4B,/O5LY'J*]G!<'Y#A\/3A4P
M='&U7%3K8O%J6(KXBI))RJSJ3J2=Y6TMMT>ULI8BLY-QG.FNE.#Y81\DNFUG
MZ=]3\N/V:O\`@DG^S-^R[\6I?B[X!UGXH:KJ]K`\7AW1O$OBQ)]#\/33*T<]
MXEKH^FZ--K<Q@=X((O$$^IV5N',R6C7<<%Q!^I%)D>HI:]S+\NP>647A\#0I
M8>@Y.:I48<D%*6\DKOXOT,ISE4DYS?-)[M[NW>Q^$7_!7G_@I?XD_95@T3X&
M_!.2RMOC+XQ\/_\`"0:UXMGABOE^'OA.^NY].LI=.L9XY;.X\4:U+97SV8U"
M.2WTG3[3^T);.XFO=.,?RA^Q%_P2FE_;`\":#^U'^VS\4?B=XSO_`(CP#Q'X
M7\(1^);Q=1NO#=\[OIVL>)O$NI#4=02/6HE^WZ7H^@#34LM(GLI'OC-,UI:_
M!G_!<CPSXBT3]O?Q9K6L03II'C+P!\.=;\)W$BN()=(L/#\/AF]CMW(V8@\0
MZ)J_F1JQ9&G1V5?.0M_5U^P+XST+QS^QA^S/K_AR:WFTY/@I\.]#D6W=&2VU
M;PMX:L_"VOV+>6`$GL==T;4;2X0@%;B*0'L:_+,`I<2\;YYA,ZG*M@LI4X8'
M+7.I#"3Y:E*/MZU*$X>UJ+F4G*2=]M-;^E5C['!T)TG:I6Y7*HOB3:5E%ZI6
MU]=-%H?.DG_!&+_@GB^GBP'P2U"/"%#>Q_$/XB#4"-I4-YQ\4&)7&2<B`*3U
M7%?E)^W/_P`$O?$/[#O@[4_VIOV)_BK\4/#6G>!7M]1\9^&/^$CN8]>T/1)+
MJ"W&NZ+X@TE=.FU;2-+N9X1K.D:Y;W4D&E-/J<E]>0VMW;/_`%59'J*^2_V[
MM3T?2?V,OVH;S7I;6/3/^%"?%6SE^U%5BDN=1\%ZMIVF6ZAR`]Q=:K=6-M;1
MY4R7$T2K\Q4'Z_.^%<DGEN,G0P6'P&(HX7$5J&+P5/ZKB*%6E2<XU(U*#IWU
MC:TKKWM.M^:AB*JJP4IRG&4XQ<)MRB[M):/JNA^:O_!(O_@IIXE_:JDU?X&?
M&W[%+\8?"OAP^(-$\7VL4=C'\0?#6FW%M87_`/:%A"J6=MXKTF6\M[B\_L](
M;35=.G?4([2VDL;_`'_N_7\-_P#P1"TG6=2_X*"_#N\TM9C9:#X+^)NJ^(9(
ME+)'H\OA&^T:'[0<86&37M5T6`,3_KY(5`9F`K^Y"N3PXS;&YMP_[3'U/;5L
M+BJF$5=KWZU.G2HSC.H_M5/WCC*=WS63TV58^E&C7Y(:1<(R2_EYMU^!_)/_
M`,'%/_);OV>?^R7^)_\`U+3[=OZ]*_>O_@F1_P`F#?LL_P#9*]*_/[7??7_/
M:OP4_P"#BG_DMW[//_9+_$__`*EI_G_2OWK_`."9!Q^P-^RSG`_XM9I0P?7[
M7??3V->/P^_^-B\5J_\`S#+17_DP/]>A5?\`W'#_`/7W]%_7W'W;112`@]"#
M]/\`/M7ZM?IU9P'XR?\`!3W_`()<^&?VM]!N?BG\*K33O#7[1F@Z>_DW`$5C
MI/Q0T^SC!@\/>)Y=ACMM9MXD6#P]XF;]Y;,(=/UAI='6.?2_R/\`^";'_!2G
MQK^QYXS?]E+]JV+7=/\`AKINNW7ANSO/$D%VOB'X(>(%NI;:?3[ZWG#W,O@@
MW3D7EE&'DT%Y)]7TH/I;SVDO]AE?B%_P5V_X)Y_#_P"/'PF\<?M&>&(['PG\
M9_A-X(UWQ=J.M0P)!9?$#PCX-TFXUF_\/>)(HQF;5[33+&4>&];):>`QIH]Z
M9M,GA^P?G/$_#^+P>)_UHX:DJ&:X92JXW#<S5',<-%)U8NGM+$M=7I._V6M>
MZA7C->PJ_!_R[=_@?7IK?2_:WS7WI^U;^V[\&_V2O@^GQ<\;:Q9:S;:Y9X^'
MGAS0;^VN]6^(FJW-LESIUIX>>(RP/IDL,L%WJ&OL6TS3=/FAN7EFFN+*UN_Y
M:/A7\*?VG/\`@L[^TOJOQ(^)&JW_`(:^$?AJ_CLM>U^SBE;PO\/O#'GBZL_A
MY\.K2Z#6VH^)[ZU9)+B>;<Z_:?\`A(?$3R;K&QOOEG]B_P""7CC]OKX^?"KX
M!^,OB7X@M_!G@;PMJUPMS?WUQJESX6^&_A^];5M2\.^#;2[>6ULKO4;_`%..
MTLPT9M;)KLWTT,UKIEO8K_=I\&O@S\.O@#\/?#WPM^%?ANR\+>"_#-FEIINF
M6:?/))R]UJ.H739GU'5M2N&DO=3U.[>6\O[R::XN)7D<FO#RYX_Q&JPQ>-4L
M#PY@:L8K`0K0G5QN.A3ISG#$NF_>HP<TG%I*5[[MVNHHX%N$8\U>491G-Z**
M;C:RL[[-;Z,J?`[X'?#C]G7X<>'OA3\*?#]KX<\'>&[2."UM($4W=]=X'VS6
M-8O<";5-9U.0"?4=1N2T]S/\Q*H$C3YE_:E_X)O?LR_MA^,]"\?_`!KTGQ5?
M>)?#WAJ/PEIMUX=\5W_AV#^Q(=4U'6(8+BU@6>&::*_U;4)4N`J2E)Q$Y=(H
M0GWO17ZG6RS`XG#0P5?"T*N$AR<N'G33I1]G\%HWM[MWO??[^"$Y0DIP;C);
M-;JY_.S^V'_P1R_8O^#7[+WQU^*W@?1?B#:>+_`'PU\3^*O#L^H>.[W4[*+5
M-&L)+VT:ZLKBT\JX@,D0BEC)4O#(Z*Z,VZOR<_X)#?L8?!7]L[XG?%KPS\;+
M7Q%>:/X*\#:/KVC0^'M<ET*4:EJ&O+I\LES<00RR31I;!E2(%`&=F))`Q_5M
M_P`%%2?^&%/VJL_]$1\=_E_8ES^?XX%?S\_\&['_`"6W]H;_`+)AX6_]2\5^
M39YDF54N.>&<'3P6'IX7$4J_ML-"'+2GIBG)N*TU_`]2C5K/!5VZDG.,XQBY
M._+:U[>NE_3S/U%7_@A;^P`I!'AWXG$9!*GXD:IA@"&VG%L#@D#.TJWH17Z[
M>&O#FE>$M"T;PUH5NEEH?A[2M.T31K&/<4LM+TJSBL;"T5W=V=+:T@BA0L=V
MU!N9CS6]17ZK@<FRO+95)X#!8?"2JQ4:CHPY.>*V4K/6VO+VN['FU*M2I;VD
MY3Y=N9WM>U[>MC\R_P#@L(<_\$W_`-I`]/\`0OAI^.?C+\.^/\^G;M^3'_!N
M.2=>_:SX'&F_!3_TJ^)PXXK]9_\`@L)_RC?_`&C\_P#/C\,^W3_B\OP[_K]/
MQZ'\EO\`@W&_Y#W[6G3_`)!OP4_]*_B;[U^>9PW_`,10X>OM_9=3>]O^8S;S
M_#N=E'_<,3_U\C_[:?U.U^(?_!5C_@J%/^R"-.^#OP?M]*U7XZ>)-%&N76J:
MD@O]'^&_AV],T.GZG=Z>,+J7B75)K2XDT;2[K%G:6ENNK:G#=PW%AI^H?MY7
M\(7_``60\,^+/#__``4$^-6H>)H+I+7Q9#X'\1>%+VX1Q!?>&O\`A!_#VA6Y
ML7<+OMM/U31M4T<A`J)=:?<(`6W,WL^(F=8_)<CA4R_FA6Q>+AA)8B*UPU.4
M*DY5(RUY*CY%&$_LW;UV(P%*-:ORSMRJ$I.+VE:UENN_]7/T:_9'_P"":7Q:
M_;V\-:-^TW^W+\<?BGJ>A>,T.M>"O!5OK3-KVK>'KF5GLM:NKK5(;O2?"&BZ
MJ@-SHVB:#H<<TFF26M\+C3X9XH6_4BW_`."+/_!/6'31IS_!W5;J0)L.JW7Q
M#^(3ZKR`&=9X_$4,"2$C<-ELL:DD+&%XK[1_93\5>%_&7[-?P(\0^#;FSN?#
M-]\(_A]_9+61B\BW@MO"^FV,E@T<+%;:XTRYM9M/N[-PDUE=6TMI/&DL+J/H
MG</4?F*Z,GX4R+ZCAJE3#4<RK5</0JU\=BY3Q=;$U:E.-25256I-[\UDET2;
M;>V,\16]I-1G*G%-6A!VC';9+;97UMIIW/R2^$?_``1F_9,^"_QCT+XO^#=2
M^*WG^&I_[0T;PAJ'C@OX>M]6C?S+6]GN--T_3=>U""T8+)%IM]J]S8W#HHU"
M*\@WP/\`K=29'J/3^O\`*EKZ;`9;@<LISHX##4L-2J5)590HQ48\\]W97WM<
MBI5J5+<\G+ET5^FU_OL?S*?\%V?VI_VB?AGXC^'WP3^'NI^)?`7PL\8>"I_$
M/B+QEX>DNM,N?&^N2ZGK&FWO@O\`X2*R:.6SL-"TW3[/4M3TJRN;674FUV#^
MT/-T]+=)N9_X)E_\$^/^"??Q[^#/AGX@?$?QE'\9?B[K4-U>>,?`EYX\NO#A
M\$W[W]Q$FC2^%]&O])\17C&V2WG?7-2O+JPU0W`O-*$5HXS_`$@_%SX-?#'X
M[>#[SP%\6?!F@>.?"5^2TVD:_817L4=P%*Q7MA,VVYTS4K;):TU/3I[74+1_
MFM[F-B:_#KXL_P#!O_\`!C5]=G\0_`SXS^//A$\LCS6^@ZC80>-]-TV0OOV:
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MG_`*Q;5/V>OVP=4\:V^FH;BT\,P>/O&7A6[NXX<OY$/A_P`5W&K>#[B20*"+
M2^U:"TERRR$_*C^:?LZ?\%J?VFOA/\6K'X1?MD:#I_B71M/\5KX*\:ZK+X>@
M\+_$GP->)J:Z1>WUW;:.EOH>M0:)>$RZA9-I,%[=00S?8-1>1H!/A3S+A_`X
M[!SSCA/$</XJ6(A]7QTJ,/JRJQLHKV^'K)K=_%"VNVC17LJ]6G45*O\`6$E'
MFI7;D[VMRJ7FG?\`-G];=%112B50ZD,C!61E.0ZNH=6'L58$?C4M?K:=]5LS
MSPJI>V5OJ%M/:74:36]S!/;312*'22&XC:*6-P<$HZ,5=01N4E2<&K=%#U37
M?0#^%7]F/5Y_V"/^"IVD>&_$UP=+T#P=\9/%/P@\1W-X3!:R^"_&%SJ7AC2=
M?NV8@#3TT_5_#7C%))#A;2*"5F$G`_NI!!&000<$$'(Y&1R/4$$>QS7\F_\`
MP7Q_91O?#OCKP?\`M;>%M.=M#\;6VG^`OB;/;1-_H'BW1+9U\(^(KUH@6">(
M/#ENNA&9GC^SW7A?3(B[2ZE&3^O?_!*']LZQ_:O_`&;='L-?U2"7XQ_".STO
MP3\1[.:8&]U2"SM#;^&/&_EDF5[?Q1IMH6OK@HJCQ#9ZV/*A@\@-^4<&5H\/
M9UG7"6(]Q3Q53,,IN]*M"K\5&,VO?J:1Y(Z.24MFK'H8F/MJ5+$QNWRJ%735
M-6Y&TN]Y;I;+<_4ZBC-%?JYYX4444`%%%%`!114$]Q%;Q//-)'%#$CRRRR.L
M<<44:&2221V(5$1%9F9B``,D@`FB]OS`_';_`(+A?'*S^%?[$VO>";>]2+Q/
M\<O$>C>`M)MTF*7/]B6=W#XF\87NU2&>Q71](&@W><(\WB*TMY"JSG'R[_P;
MT?!V;1?@[\;/C=J-JT4OQ$\8Z'X)\/S318>71?`.FWE]J-[;LQ;?;WVM>+9-
M/E8E@9_#_EX_<EF_*'_@I'^T=K__``4(_;.T'X=?!V.7Q'X0\+ZQ:_"'X/65
MD6FM?%&MZMJUO::]XPA9=ZI;:_J_D16U\PB">%=!TW4+D1AKJ%?[!_V7/@5H
M7[-/P(^&?P1\.LL]EX#\+V.EWE^D9C75]?N#+J?B?7/*QE&UOQ'?:IJC1MEH
MOMBP`A(D1?R;)YKB3CC&YU!^URS(J/U'"5TO<EB)?NN:&JM:=6O6>_Q*-_M'
M?5E'#X2-%N]6K^\<=K*7+97N]M-;+T[_`$37XI_\%MOV>_C/^T1\!?A-X<^"
MGP_UGXAZYH7Q;36]8TO0VLOM=AH[^#O$FG_;WBN[FU\R%;RZM[=O),C+)/'N
M50:_:RBOT7.,KI9SEV)RW$59TJ6*I>SG*FH.?QTYWCSQE_):RMI+79')2J.E
M4C42NX]+V1^1W_!&#X)?&#X`_LH>(/`OQI\"ZS\/O$\WQB\5>(+#1=<-B;V;
M0]0\-^"[.VOPMC=W:I#+>Z9J,*"5HY";=G\L(R$_I)\7_@_\/OCOX`\0_##X
MH^';+Q3X*\3V3V>JZ3>IU.5DMKVSN%Q/8:GIUPD=YINHVCQ7EA?0P7=K-'-$
MCCTW.>E%+`Y1AL#E6&RA+V^%P^&CA>6LN?VE))*TU?7;373H*<W.I.I:SG)R
MMT5^GF?Q(_M1?\$=?VL_A%\1_$'A3X%^$/%?QK^#VMW4.MZ#J^@SZ?%>0PVK
M:BFF:7XTTB:_LHCXCT&.]N+:VU2W@EL-0M;FXO;!K.>]OK*T_I*_X)1?"3XC
M_!#]B+X8_#CXK>%-1\%>-M(UCXB7FJ>'-5:V;4+"+6?'_B35K`S_`&.>XA7[
M3I]W;74:B7S!',ADCC;(K])**\#)>!\KR#,\3F6`JXF/UBE.DL+4J<]"A3G4
MI5/9T7*]7V2]GRQA.I/ENVFM;[5,3.K3A3E&-H24KQ7*W;9.V@5^7'[?_P#P
M3#^%O[;6FV'B'^U)/A_\:-`TIM,T'XA:?8I=V^J6$+236NB>,=*22!M5TNWF
MGE-E=VMQ;:MI?FO]FN9;9I+*7]1Z*^ES'+<'FV%J8+'T88C"U%[]*:37,K.-
M2#?P5:>KA-)N-WW,(SE"2G!\LH[/MW/Y>OA'\/?^"R?_``3ZMAX%\&>!=!_:
M7^#.F2-_8^A6NKP^)+#3+1Y78)X<AN-2\->._#T3A?-?2!9W^BV4TSR06DCL
M9#]3:?\`\%(_^"A-XATN/_@EO\2#X@5`C32ZWXEL-&,I8%6$MYX+A1(OF+$'
M4,KG86?:#7[OT9KYW"\*8G+J?L,MXFSG"X6+_=X>M'+L="C'2U.C/&X*M5IT
ME:T8<[2ON[(W^L)_'2A*5[N4?=<MM][[?GW/R`^`/Q5_X*P^/_BUH.K_`!@_
M9U^"WPL^!\^ZV\0^'M0\6&/QG!IT[H4UG2KS3=5\87EWK.FHQVZ5J.DZ5IVH
M"2:SG.G2F&\M_P!?Z**^AR[!5,!1E2JYAC,PE*;G[7&RHRG%NUXP]C1H\M/;
ME@^91Z/4QE)2M:$86O\`"K7]3X1_;F_81^%/[;GP\L?"WC9KG0/&/AHWMWX`
M^(FD6L$VM>&;VZ@$5S:7$$C11ZOX?U%8X$U319YH/.$,=S:7=E>P172?C'\$
M?@O_`,%9/^":,NM>#_AA\.O#7[3OP.U#5Y=9CT'1]4^W0VMU.$6;4=(TNXO]
M%\8>&=4OXXXO[2L;>R\0:$9D$WDW-P))Y/ZBJ*\?,^%<!C\=#-*-?%99FT5R
MK'X"<(5:L5:]/$4ZL*M*O2=E>$X.VMFKFD*\X15-J-2DG=0G&]O1WNC\+E_X
M*;_MS1PFUN/^"6/QD;5U_=,T&J^)_P"S?M!'!WGX<.1"#@%Q<.I!)#_+S\F_
M'GP-_P`%<O\`@I#9VGPV\3?!;0/V9O@C/J=I?:KINOZU'I2:D;*Y2ZLW\4W$
MMWJ7C3Q%'I\I%]9Z=IOAS3-(FU*"SN[BT,MLES!_4'GOV]:*PQ'"U?'4987,
M.(LUQ.#FTJ^&IQP.#A7BM/9UJF%PU.K*F^L.=)Z7&JZA*,H4H*4=G+W[;;)[
M;?UU_-[]@#_@G'\-/V&?">HMINIR>-?BOXMMK2+QS\0[NT6R%Q;6D@NH/#WA
MS3A),VD>&[>\!N7BEN+F]U6Z6*\U.9WMM.M]/_2&BBOH<OR_!Y5A:6#P-&&'
MPM&"A3I05DDEK*3^W4E:\IO5]=C&<Y5).<WS2EN^Y_-=_P`%N?V2?VE/VC_B
MM\$O$'P2^$7B;XC:/X>\`>(-(UJ^\/G3GCT[4;CQ&M]!;7*WE_:S!YK21)D9
M8C$PWJLAECFCB@_9Y^/7_!6K]GGX,?#SX+:)_P`$^H?$6D?#KP];^&M-UC5K
MR_@U&^L[6XN9H)KR*R\41VB3K'<"%C`B(PA5@B;MH_I8HS7S%3@V#SC'9W@\
MYS+`8O,(PA66&^JNFX0]@K6G0E_SY?;XM;V1LL0_91I3IPFHWY926JO:]NFM
MC\#_`/AN/_@L!T_X=OZ/Z?\`(3UG_P":JOUK_9@\9?&3X@?!?PEXO^/GP\TW
MX4?%'6H]5N/$'@#2[R:^AT""#7=5LM%BGN)[B[D^V7NB6^G:C>6YN9C9SW;V
MCLLT,L4/T+17KY=E&,P59UL1GN8YE'EY8T<7'"^SC+2T[TZ$*EUV4XIZ7O9)
M14J1G&RIPAWY;Z[+K?71V]7N%>`_M1>&M=\9_LW?'SP=X7TV;6/$OBSX,?%'
MPSX>TFW,23:EKNN>!]<TS2-/B>=T@26]U"ZM[6(RO''YDJAY$!S7ON1ZBES7
MKXBC'$T:M";M"M2J4:G+I+EJTY0:3^S\5_.UO,S3M)2[/]4_T/Y0O^"/G[$_
M[57P#_:\_P"%@?&'X*>+?A_X/A^%WC;26U[7_P"S(K,ZEJ-SH(LK&,6NH74[
MW%P(9G4+"55(9&=@!S_5[117D</</X7AO`RP&#JUJM*5>IB+UO9\_/5Y>;6$
M(W^%:NYK7KSQ$^>6EHQBEOM?7YA11FBO>,3Y0_;@\&^*OB-^R)^T-X"\$Z+=
M>(O%WB[X3>,M#\.Z'8M"+W5=6O=)FAL]/MOM,D,`EN966-#+-&ID*KN!8"OQ
M>_X(C?LE?M)?LW_%+XX>(/C=\(O$_P`.M)\0>`/#NDZ)>>(/[.1-3U"W\1/>
M3VEHMG?7<SS16ZASF-8AO7?(&:-)/Z4**^<QG#6$QN>9=GTZV(AB<MISI4J4
M'#V,XS55>\IQE:WM-.6WPZ[Z;*M*-&=&*LIRYF]^B25OEOYA1117T9B?`O\`
MP4[^&?C[XQ?L-?'/X;?#+PS?>+_&WB6Q\##1/#NF-;B^U%M)^)W@G7+]+?[5
M+!"7@TO3;V[96E7,<#A"TFR-_P`V_P#@AO\`LL?M!_LVZG^T?>_'#X6^(OAQ
M!XOL_A1:^'&\0_8(Y-7FT:;Q[)JBV<5E>WCE+'^U=/\`/EE$2`S@)N*/M_H>
MHKYS$\-X7%9_@N()U\1'%8&A.A2IP</9.,_:K52C*UE5=K+IJWTVC6E&C.C'
M13ES.77965OE^(5\"_MU_L"?"3]N#P18:-XT>Y\,^//#4=T_@7XDZ+;0SZQH
M$EQ&#<:9?VDC11Z[X;OY5$E[HUS-!ME'VNPO=/NM]PWWSD>H]*,CU'I7K9AE
M^%S/"U,'C:4*V'K0<)PFD[IV]Z/\M2+MR36L6W;<SA.5.2G!\LH[,_EF^&/[
M,O\`P5Y_X)S7NHZ1\!K7PS^T-\&VU&;4?^$.M=3MM3T:9I)I9)KRU\*ZYJ?A
MSQ7X8U>[5@]['X3O[NSO)W66Z.I2QEZ^L])_X*2?\%#H%CTG6/\`@EM\1KOQ
M"5V/<:9J/BFQTB2=5`W+]H\&:C'#&\I;:IU>Y"(/FN&X)_>>BOF\-PG5RZG[
M#*>(LXR_")KV>$Y<OQE*A%6:IT)8W!5ZM.FND.=I&WMXRUJ4*<Y=97G"^VZA
M))[=;GXK?#OXV?\`!7_XD_$/PIJ^I?LI_!SX3_"J'5%D\2^'?'/C'R/$.JZ)
M,!]HBCUBSU?7]8L-3M$8W%G)%X,CADNH%BO+.2UDD"_M329'J*6O?R[`5<#&
MJJN8XW,959J;GC'0;INSO"BJ-&ER4]5:FW)1M[K5W?.I4C.UJ<*=K_#UO;?Y
MK3U/QJ_;&\4?\%<?#GQ9?7_V4_!7PP\2_!72;"TM+'PN+CP[JOB;7KDQ1W&H
MZOXG@\53>%M2L[@S;[*PTWPIK$EO!:1QO-<7-U,Y3Y\T7_@HW_P4_P#"!2Q^
M)O\`P39\1^);B)(TGOO!6F>.M+CE*`*\JK%9>.K)O-`W((;N-!G@'9D?T,45
MY%?AW&2Q-?$X;B3.,-*O/VCHMX7$8>D_Y:-*K0_=TTOA@G9=6]+7"M&,5&5&
ME*W7EL^F]O0_GP\3?\%!/^"HOQ*T]]$^#O\`P3I\3>!-;O#]GM_$OCJWUW4;
M;36F^1;J*WU_3O`FCI)#)M=)=3NKFQ4JHN+>13AOGS]F#_@C#\;?B!\9D_:%
M_;K\3::DFI>+F^('B#P!I.I6^O\`B/QIXAN=0;66MO%NM:6D7A_1M*DU$E;_
M`$[19-2ENK(-IEO)HZ2AK?\`J2S29'J*YI<'4<9B</B<ZS3'YS]5JQK4<+B'
M0I8*%5)6G]7H4X*3T5N>4K6TMK>UBI0C*-*$*7-;FE!>_IJK2W77U$1`@PH`
M````&``H"@`#H```!VIU%%?9'*%%%%`'D_QN^#/@?]H+X8>,?A#\2-/&J>#/
M&^AWFBZM:J$6Y@>;RY;#5].N'1_LFKZ'?P6VJZ1=A'^RZC:V]QY;F)17\2FJ
M:?\`M%?\$@?VR4GMT>\@L)IGTZXN8[BS\(?&CX3W=\)7MYBIF19&AM(S=0J\
M^H>$_%E@L\*SPV=M>7W]X=?)O[7/['OPB_;&^&%S\./BGIKF:#S[WPAXRTR.
M&/Q1X'UYH0D6KZ#>-&Y$,C+''J>EW'FV&K6P6*[B:6*VN(/B>+N%IYS3P^.R
MZO\`4\[RV7M,#B8WCSVY?W%:2=W&7*N65GRZZ:G7A*\:4Y1J*]*K'EJ>75/S
MMKZ?>6_V3?VN?A%^V)\+K+XF?"O6(7"I:VWBCPI>7$*^)_!.O2Q>9<:'XAL`
MWF02(5=K"_C5K#5K0+=V,[J98X?J>OX3/BO\`_VV/^"3'QEA\>^%=9UK3?#_
M`-M-GX=^+7A:SNKSX?\`CC26F\V'P_XTTBY^TZ=:W5U';P?;O"7B5&9KJ,W&
MA7U\;>TU-?VK_9._X+R_!/XAV.E^&OVF]$G^#GC-DAM[CQEI%MJ&N_#36+G$
M:?:VBM8[[Q-X7-U,X`MKNSUC3[8'?<:Y%"/W?F9%Q[AW-Y5Q-!Y/G-"7L:DL
M3%TL)B''3VJQ#7LJ5[K24K._NR=G:ZN!DDZF&<:E)ZQ47K%)+1]5>^GG?I:_
M]!%%>:_#;XP?"[XO:2-<^&/Q$\$_$'2&2.47W@[Q-I'B"*-)5W(+H:9=7#VD
MN"-T-RL4RMD/&IQGTDL!U('U('^>M?HE&M3KP52E4IU8/:=.2G%_-'#KV%HJ
M.6:*&-YII8XHHT:2265UCCC102SN[$*J*`2S,0``23Q7P/\`M`_\%,/V.?V<
M+"]_X33XQ>&_$/B2T641>!_AW?6_CCQ5<W,0<?8YK71)9K#1924;YO$>IZ-;
M@*P,WF`1MSXS,,'@(>UQF)P^'IJ]YUJU.DE:VRFTY;ZVNT7"$ZDE&$7)O16_
MSV/OLD*"6(``R23@`#J23P!7\O7_``5T_P""K.F7^E^)OV4?V;O$$%^U\+G1
M?C#\3M$O!+91V19[;4?A_P"#]0MG,=W/=;6L/%VMV\YM5LI+O0;%KI[R_P#L
M_P`:?MD?\%>?VAOVPKR7X-?`?P[KGPP^'?BB\&A1>&_"AO=:^*WQ#CO9#;Q:
M;JNHZ)']J@M=41A%-X4\,PYN8GN;34]4U>T<JOW-_P`$U?\`@C%/X>U#0_CM
M^V%HMO)K%B]IK'@KX(W7DWUII=X&2YM-:^([`S6M]J%K(OFV?A2W:6V@G*3>
M(9)KL3:/8_F6:<29CQ=5>1\)1JPPLW_PH9[+]W0I8>ZYXTII-WE:2;3UT.ZG
MAZ>'C[;%.SWA32O*=K<UK]KQOMHSJO\`@B?_`,$ZK_X>V,'[77QHT.73_&GB
M#2FA^#7AG4[39>>&?"^LVK)?>.+^WGQ)::WXGTZ;[)H4)1);#PW=75S/YQUX
M067](-06]NENNR/`4`*H"A0JJ6*HJKA0J!MJA5'`&<GFIZ_0<AR3"</Y=2R_
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M\ONW.=^-?[?_`,9OV=O!-]X^^(GPY_95\0Z9I>R2Y\.?#W]KS[7XZU.%[F&`
MQ^&/#?B7X2:$WB+45$P9-,T^ZENYPDABC(4!OT,^`OQ<7XZ?"7P-\54\&^*O
M`"^-]`M==3PCXVLH]/\`$FD1W3SQQQ:A:Q2RKY=RD`OM/N,QF]TNZL;UK>W-
MQY"?F#\3?V-?C/\`$7P9X@\*Z;^R!_P3J\!:MK&DWFGZ=XTM)_%.IZOX9NKE
M%1-;T2'2?@[X7ODUC3?^/K2YK?6[#[+J"6MT6D2%K>;[=_8?_9Z\>_LP_`K2
M?A1\1OC!KWQK\1Z?J>H:H_B;7$NTBTFVU);;RO">@_VE=W^IMX>T>2WF>P;4
M+R:<O>W)C2TM?L]E;>3E-3/%F<XXB%>IEM3!IJJZ5"E&CB8O=SY:->M[52?\
M.E-4W#W^7G7-=6-+EO3>J>JZZ\MNKVU[?)Z'V%7(>/?%/_"%>"_%GBT67]H_
M\(QX9U[Q%]B,WD+=_P!B:5=ZI]D,PCE,/VE;4QB40S>7NW^6V,'KZXCXDZ#>
M>*_`/C7PKI[PQ7WB?PEXE\/VD]R76W@N=7T:]TZWFN#&KR>1%-=(\WEI)((U
M8I&Y&*^KKJJZ5147^]=*HJ;?_/RRY&[];W=O4YSYC_8,_:QNOVS/V>])^-][
MX+@\!7&I^(?$V@2^'K?6I-?AB/AW4#8_:5U"33M+=Q=+B3RC:CR^5\Q^M?:=
M?`?_``3:_9A\=_LC?LQ:'\&/B-JGAS5_$VG>*/%NO7%]X4GU*ZT8V^OZJ]U:
M6\,^JZ;I-W)-#;K']H9[&)1*YC7.S)^_*X<F^N?V;@O[14HX[ZK2^MQFES.N
MDU.3M=:Z;-FE7V?M)>Q5J6G+]VO];WN%?F5/_P`%`]9^)_Q[^(7[.O[*GP@M
M_BUXG^#\K67Q7\?^,O&R_#WX8^#-734Y]'GT:*]LO#WB[Q'XCO[;4K+4-/G3
M3-"B3[7I>I_9VN+6RFND_36OR*T;]AGXO?LV_M,?%O\`:&_9(\3>`M6T/X[W
M<^K_`!-^"_Q?.OZ-IL>OS:KJ'B$ZQX1\=^%]+U^\TZ3^U]5U>>WTS4O#=_9V
M,>JW-HK7<:Z?_9_/G;S12R_ZA[58;ZT_[3EAH4YXR.&5*3@L/&JI4W[2MR4Z
MG-!M1FII^[9E-T]5/XG;D6R=G[UWTZ?B>M_%G]I3]K[]GOP5K?Q1^(O[.'PN
M\=_#_P`*Z=/K?C#_`(5!\9->G\9:%H-@GGZOK=IH'C;X:^'K#7;32;)9;^[M
MK76K:^^S12.L.Q)98OJ']FW]HCX??M2?"7PU\9?AE>7%UX3\2PW"Q17\'V35
M=+U33KRYT_5]&U>S$DRVVH:;=VKQS)%/<6\J/%<V5U=V,UK>7'R5\>O"/[>O
M[0?PM\7_``AM_"'[//P2TGX@^'M7\'^)O&\'Q4\??%+7;/PYKUC)IVN_\(WX
M?@^%/P_LTU.^TV:XM+5]3UOR(5GDR3,T3K]`_L9_LN^&/V/_`("^%?@?X6UG
M4?$<6ARZCJNM^)-5BCM[S7_$NO7<E_K&HFQA>2'3;<RNEM8:<DMP]IIUM:13
MW=[<>;>3\N#JYE+-K0CC)Y2\&W4J8^DJ52.+C;E]AS0IU?>3E[3VE-6M#DNK
MM5-0Y6^:/.K6C%WNM$VW]FW31WNWI8^K:\J^*VJ_%[1]`LYO@QX0\!^,_%$V
MJQ17FG?$+QKK7@?1(-%%K=O<WD&J:#X/\;7ESJ"7:V4,5@^EP026\US.UXLE
MO%;7/JM%?15J;JQY8U:E%Z^_3Y.97[.<96^5OR,3\>#^WI^U:/VLE_8Y_P"&
M;_@H?BDW@IO'O]KCX]>+?^$(&A"R-X,ZG_PIS^V_MV[_`$<V@\/&,288W`AW
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MB;3!=^3<FT:^&FFU6X^S7'D&7S3#(J$5ZG7B_P"T)X%U;XH?`GXS?#'0KBRM
M-:^(_P`*?B-X#TF\U)IX].L]4\7>#-9T#3KK4'MHI[A;&WO=1@ENV@@FF%LD
MK0Q2RA(G]O&JK]5Q#H:UHX?$.CYU?8SY/Q_&VAFM9*.REN^VJ_SO\C\[?V>_
M^"@_QL_:.^%NB?%GPI\,_P!EKPGH>O7>L6EIHWQ$_:MU3PYXJ@?1=3N=)N9+
MW2+3X+ZNEK%/=6DLMD7O#)/9M!=>6J3IG](_@]XD^(OBKPI_;'Q+\/\`@'P_
MK-U=M-ID7PV\=ZE\1/#6H>'YK>"33]2C\0ZGX0\%RM<W,IN]]M!I=Q:I;I;3
MQ:A<&X=(?QS_`&8OV`OCO^S]\']"^&'B7]F/]@KXS:OH]]KMY/X_\9:QXA?Q
M)JL>LZS>:I!#J4M[\$-8GE.F0W4>EVKF^=#9V=N%CC.\'];/@%9?%'2/"<VA
M?$KX?_";X<+HDEEIOA'PY\'?$.L:WX6MO#EM8Q1PPB'5_!W@Q=(EM9UEMH+#
M3K&>Q%G%;R*\$K26Z?-9!6S.<,)'-%C%B/JLO;PG2_<*M[CGSU:,'AE?2R=6
M7,D[;&M>--3?L];[Z?=KN_G^I[O2%@H)8@``DDG``'4DGH!W-+4%Q;QW44D$
MRAX98WBEC8`K)'(`LB,""-KINC;C.US@@\U]@[]#$_,?P?\`\%"-<_:/^('C
MOP#^QE\'+7XO:1\,[Z#3/&GQB\=^.4^'/PKL]2NYK^*TL]`>Q\.^+_%?BQKH
M:9>RP3Z?H%K;-;PI>^:;"ZL[NX^D_!?BO]KMO&&E:=\1OA+\"[3P5>^<=5\4
M>"OC%XRU#6]&"0N\*P^&-<^$NF1ZN\LNV)576]/5(V>:26/8D4WQ+\#_`-A[
M]H']A_Q;\1I/V2O$_P`+O'/P;^)/B%?%5W\(?C7_`,)1X;UKPIJ\=N]HJ^%O
MB1X6TWQ$UW!]B2VLBNM^%Y2+.TM4=9;R.XU2Y^VO">N?MB:KXHT`>.OAS\`/
M!G@U+N7_`(2-M!^*/C[QYXHFL?LTH0Z'#/\`"WP1I-O.MVT!;^T;FXB:%)@B
MF0Q2+\CE=7,JBA+-99E2QTL3-2P]&A">7TJ<*LHPE2JTZ51U:511O&4JLFGM
M&.KEN_9\S5)QY%:TIMJ<DTF^EW9W^];GU91117UQ@>+_`+0_Q4D^!WP/^+7Q
MBBT9/$4GPR^'GB_QPFA27C:<FK/X8T*[U:/3VOTMKQK5;N2V2)YDM+F2.-G=
M()64(?#OV3/VU_A[^T=\`O`/QC\0:QX$^'&L^+[;67U+P5>_$#1+NZT&ZT?Q
M)K/A\V\L]\VD7;"ZCTF/4X!<:=:R?9K^'Y&39-+ZW^U'\-=<^,_[.OQL^$?A
MJYT^R\0_$KX7>-_!&C7NK/<1:7;:KXB\/WVE6,U_):6]U<QV:7-TCW,D%M/)
M'`DCK$Y`4_*W[&?[`?PT^"?[.'PU^&7QD^%'P2\=_$?PS8ZVGBGQ2G@;P_XB
M_M6\U7Q9XAURV?\`MGQ!X<@U:^^RZ9J=AI[37<,3AK,PI&((8J^8Q$LW6=48
MX1TO[-EEU:4I5G4C2EBY8M04(RIPJ-U>6;<8R44^5ZV5UNE35&4IOWVURZ:I
M1W];JWI;SN:7@C]OC3/'O[=WBC]CKP[X9T+5]"\.?"Z'Q\GQ0T;QC;ZM!?7[
M6GAR]N-$32;*PFLT6WB\0K%)-_;+7"3VY#VH1CL_16ORD^&/[!6L?"O_`(*-
M>,?VJ_"%A\-?"7P5UWX0)X(TSP3X4L9-%UBS\0O;>%;:\O9-"T[1;30(;6Z?
M0KBZGNX=1:ZFDEB$UN9BS']6ZZ\B>9NCC%FJ2K_7\1['EES0EA7R^QE2>CE3
M>O+)J+?5:7<U73_=^S37[J'/YS:NWY7[=-`HHHKW#(****`/`_VF?C'-^S[\
M!/BI\:;?0(_%$OPV\':SXK309;]M+CU5M,MQ(MF^H):WS6HF8@>:+2?:`?D+
M%0<G]DSX[3?M,?L\?"[XZ7'AN/PC/\1=!FUF;PW#J;:Q'I4D&KZEI+VZZD]G
MI[70)T[S=[6<!7S/+*DH26?M<_"CQ!\=?V9_C1\'?"MWIEAXD^(W@'7/"^BW
MFM274.DP:CJ%J4MWU&>RM+Z[AMO,VK+)!9W,B!MXA<*16)^Q-\%_$W[.O[*_
MP>^"GC"^TC4_$OP^\-W.CZQ?:!+>7&D7%W<:YJ^K`V$U]9V%Y)$D6H11%YK.
MW=I(V81A",^$EF+S]1Y*BRMY795.6/L_KD<<GOS7YN379.VIKR)T':5FZJI_
M]NVC[U]O*VF^^Q]84445[ID?AUX;_P""RVD6OQD^*'A'XL?`_6?`_P`%_AQ\
M8?$'P8U/XZZ+KL_BK1_#?B6PUW6M)\/3^.M$@T&UNM"TOQ+#H=]+%J-M<7JV
M=W#+9I;WOE3S0_6W[8'[>.G?LTZ-^SAXC\+>$])^*OA_]H#XF:%X)L=9T[Q9
M'9:;::+K<=G/!XATB^LM,UBUUD7%O>)/9();:SDC1F>\`/R^9?L>_L&>(OA-
MXK_;E/QQC^'OCWX<_M2_%*?Q?I'AFU6]UJ!_#EWKGQ`U*>Q\5Z=K6BV%I#?&
MV\5Z6D<=C<:G%%<V4MQ%=H\5NQ^0_BW_`,$B?C!;^+_AQX:_9_\`B[IJ_LQ>
M$OC-X7^,=G\)?BE?:_?:I\,=7TB^D.MZ;\.=;M]+UB>^T+5M/NKF2+1-4GT]
M;?4$CNKF\O;I3J<OYQ[7C"CEM24J-3$8C$8N4*</]GHXK!168QI0G*/N1KX7
M$8.*E[:ZG2]K)>S:C>7;_LDJB3C:$%[R5W&I>RWLN5KROOM?4_H8HHHK]&6R
M]$<1^?/[07[??A/X0?&;P=^S'\._`GB#XX_M)>.X4N](^''AW5-+\/:9HNG2
M6%_JR:KXU\8:QYMCH%E_8^F:AK)BM['5;U-+M3=W%M;I<6?VCJCXS_;VCMH+
M\_`G]FR<N8WG\/Q_M`>/(=4MHI&`>/\`M:3X)/IDUQ!U<I`L,NUA$QQD^*?M
M"?L&>,=6_:@\-_MK?LV_$;1/`_QZTG1E\.>)/#WC_P`/77B'X;>/M#719/#A
MM]2?2KJUUWPY?OH4D&G2ZEIQO?-ATO2Y(;>TO+>YN[[V^V\1_MZRVHL;CX0_
MLO66HA"C>(?^%V_$J]T@S`*/M2^&D^"]MJ!A8EV2W?Q`KJJ^4UZ2PDKY&E/,
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M36M]I^H07-G<P2+]^.>&1#@<8SG\.OVF?^"#7[./Q,NK_P`1_`KQ'K_P'\17
M[RW#:);P-XN^'3W6XR'[-H-]>6>M:"L\LC';I&OKI5G$N+;1/E$,O[T45XN9
M\/93G-+V.9X.CBDHJ$*C@HUX15M(5E>2O;I8TIU:E*2E"7+W7?M]Q_%'XS_X
M(F?\%!OA+J[7_P`,8/"OQ`-J[S6&L?#?XB0^%M6C5&54=[;QA)X+N;6[9-C;
M;:^OUC&4265X@PYM/V?/^"U?A\?V99V?[8T$4&%6+3/BEXFN;)%`"JL,^F>-
MKBR<<$_NI"5S\Q.17]P%%?'R\,<IAI@\TSK!4]/W5+%QG3TM:T:E.7+L]M[Z
MWLCH^NU/M0I2=]^3T_R1_#M-^P'_`,%=/CALLO&?A+XSZU82G,\WQ7^,-C%8
MQJQ4@SV'B?QQ+>L>6QY6G74R[!NC96"GZU^"7_!O;\5]6NK/4OV@/C!X7\&Z
M67$]WH/PVM;WQAXBG3>CFUDUK6;70]$TNX/[P_:;:R\3Q;BQ,4A82I_6I15X
M7PQR"E55;%U\QS.7VH8W$1E1G_CA2ITYV711JQ\[@\=52]Q0I]^56NM+?=8^
M)_V7_P#@GW^R_P#LBV4;?"7P#`/%36QMM0^(WB:9?$'CW4D=-EPKZY=Q!=+M
M;D9:XTSP]:Z/I<KYD:R,DDCM]L445][@\%A,OH0PV"P]+#4(?!2HP4(1]$M#
MEG.4Y.<VY2>[>["BBBNHD****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
4*`"BBB@`HHHH`****`"BBB@#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
